Dr. Mitchell is the Director of the Center to Eliminate Cancer Disparities in diagnosis, treatment, and survival of patients with different ancestries. She is the President of the National Medical Association, and has published over 50 papers, chapters, and reviews on translational clinical trials of chemotherapy and molecular therapy for advanced cancers, including breast cancer. Dr. Mitchell is responsible for efficacy experimental design, analysis of experimental results for relevance to clinical deployment, and design of a future Phase I clinical trial.
Dr. Dang is the Scientific Director of the Ludwig Institute for Cancer Research. He successfully launched several Translational Centers of Excellence, which propel teams of scientists, nurses, and clinicians to reach for the cure for various cancers. Dr. Dang established the Center for Personalized Diagnostics and the Basser Research Center for BRCA. He has held numerous international awards, including an NIH/NCI MERIT award.
Dr. Damha is a professor and chair of chemistry at McGill University. He has co-founded Anagenis, Inc., an RNA therapeutics company that was later acquired by Topigen Phaemaceuticals, Inc. Dr. Damha is an expert in developing protein and RNA targeting drugs. He has over 160 publications and multiple patent awards worldwide.
Dr. Zhang is the Dean of School of Pharmaceutical Sciences at Beijing Medical University. He is also the Director of the National Key Laboratory of Natural and Biomimetic Drugs, and an elected member of Chinese Academy of Sciences. Dr. Zhang is an expert in the chemistry of nucleic acids and anticancer and antiviral drugs. He has 120 publications, 2 patents and 2 books.